How to Help Your Patients Save Money on Vijoice 50 Mg 28 Day: A Provider's Guide to Savings Programs

Cost Is an Adherence Barrier You Can Address

As a prescriber or care team member managing patients with PIK3CA-Related Overgrowth Spectrum (PROS), you already know that getting patients on Vijoice (Alpelisib) is only half the challenge. The other half is keeping them on it. With a cash price of approximately $31,754 per 28-day supply, even insured patients can face significant out-of-pocket costs that threaten adherence.

Cost-related medication non-adherence isn't a patient failure—it's a systems problem. And providers are uniquely positioned to intervene. This guide covers the specific savings programs available for Vijoice, practical strategies for integrating cost conversations into your workflow, and resources you can share directly with patients and caregivers.

What Your Patients Are Actually Paying

Understanding the financial landscape helps you anticipate where patients will need help:

• Cash price: ~$31,754 per 28-day supply (all strengths priced similarly)
• Commercially insured patients: Copays vary widely. Specialty tier placement means patients may face copays of $500-$3,000+ per fill, even with good insurance.
• Medicare Part D patients: After the deductible, patients in the coverage gap face significant cost-sharing. The Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) provides some relief, but the initial fills can still be a shock.
• Medicaid patients: Generally covered with minimal copays after prior authorization, though state-by-state variations exist.
• Uninsured patients: Facing the full cash price without assistance, which is effectively inaccessible.

The patients most at risk for cost-related non-adherence are commercially insured patients with high copays and uninsured patients without access to assistance programs. Both groups have options—if they know about them.

Manufacturer Savings Programs

Novartis Oncology Universal Co-Pay Program

This is the most immediately impactful program for commercially insured patients:

• Eligibility: Commercially insured patients (not government insurance—Medicare, Medicaid, Tricare, and VA are excluded)
• Benefit: Eligible patients may pay as little as $0 per prescription
• Annual cap: Novartis covers up to $15,000 per calendar year in copay costs
• Enrollment: Call 1-877-577-7756 or visit Copay.NovartisOncology.com
• How it works: The copay card is applied at the specialty pharmacy. Once enrolled, the discount is typically automatic for subsequent fills.

Clinical pearl: Encourage enrollment before the first fill. Patients who see a $2,000 copay on their first call from the specialty pharmacy sometimes abandon the prescription before they learn about copay assistance. Proactive enrollment prevents this.

Novartis Patient Assistance Foundation (NPAF)

For uninsured or underinsured patients who cannot afford their medication:

• Eligibility: Patients who are uninsured, underinsured, or who have been denied coverage
• Benefit: Free medication provided directly to qualified patients
• Enrollment: Call 1-800-277-2254 or visit pap.novartis.com
• Documentation needed: Proof of income, insurance denial letters (if applicable), and a completed application signed by the prescribing physician
• Processing time: Typically 2-4 weeks after complete application submission

Clinical pearl: The NPAF application requires prescriber involvement—your signature and NPI are needed. Designate a team member (nurse, social worker, or patient navigator) to manage these applications so they don't bottleneck on your schedule.

Independent Copay Assistance Foundations

Beyond manufacturer programs, independent charitable foundations may offer additional support:

Patient Access Network Foundation (PAN)

• Provides copay assistance for specific diagnoses and medications
• Fund availability fluctuates—check current status at panfoundation.org
• Can be used by Medicare patients (unlike manufacturer copay cards)

Other Foundations to Monitor

• HealthWell Foundation — Periodically opens disease-specific funds
• NeedyMeds (needymeds.org) — Comprehensive database of patient assistance programs; useful for identifying additional options
• RxAssist (rxassist.org) — Another database of patient assistance resources

For Medicare patients specifically: Manufacturer copay cards cannot be used with government insurance. Independent foundations like PAN are often the only copay assistance option for Medicare patients. Monitor fund openings and enroll patients quickly when funds are available—they often close within days.

Coupon and Discount Cards

For a specialty medication like Vijoice, traditional discount cards (GoodRx, SingleCare, RxSaver) have limited utility because:

• The cash price is so high that discount card savings are minimal relative to the total cost
• Vijoice is dispensed through specialty pharmacies that may not accept all discount cards
• Manufacturer programs and PAPs typically provide far greater savings

That said, for the rare patient who falls through every other safety net, checking these platforms is worth the 5 minutes:

• GoodRx
• SingleCare

Direct patients to our comprehensive savings guide for additional options: how to save money on Vijoice.

Generic Alternatives and Therapeutic Substitution

Generic Availability

There is no generic version of Alpelisib (Vijoice) available as of 2026. The medication remains patent-protected, and no abbreviated new drug applications (ANDAs) for generic Alpelisib are currently pending.

Therapeutic Alternatives

If cost is truly prohibitive and no financial assistance options are viable, therapeutic alternatives to discuss include:

• Sirolimus (Rapamune): An mTOR inhibitor used off-label for PROS. Generic Sirolimus is significantly less expensive (~$200-600/month depending on dose). While it targets a different point in the PI3K/AKT/mTOR pathway and has a different side effect profile, it was the standard systemic treatment before Vijoice's approval and has published evidence in PROS patients.
• Surgical intervention: For patients with localized overgrowth, surgery or sclerotherapy may manage symptoms without ongoing medication costs, though these approaches don't address the underlying systemic disease.

Important note: Therapeutic substitution for a rare disease treatment should involve the full care team and careful consideration of the patient's specific manifestations. Vijoice is the only FDA-approved option for PROS, and switching to off-label alternatives should be a last resort driven by true financial inaccessibility, not a first-line cost management strategy.

For a clinical overview of alternatives, see our article: alternatives to Vijoice if you can't fill your prescription.

Building Cost Conversations into Your Workflow

Many providers avoid cost conversations because they feel uncomfortable, time-consuming, or outside their scope. But for a $31,754/month medication, ignoring cost is ignoring a major barrier to the treatment plan you just designed. Here's how to build it in efficiently:

At Prescribing

1. Name the cost upfront. "Vijoice is an effective treatment for your condition, but it's also very expensive—about $31,000 per month without assistance. The good news is that most patients pay little to nothing with the right programs. Let's make sure we get you connected."
2. Initiate copay card enrollment immediately. Don't wait for the specialty pharmacy to deliver sticker shock. Have your staff start the Novartis copay enrollment (1-877-577-7756) during the same visit.
3. Order prior authorization proactively. The faster PA is approved, the faster the patient gets on therapy and into financial assistance programs.

At Follow-Up

1. Ask about cost at every visit. A simple "Are you having any trouble affording your medication?" catches problems before they become non-adherence.
2. Watch for signs of cost-related non-adherence: missed refills, dose stretching, requests for smaller quantities, or vague statements about "taking a break" from treatment.
3. Reassess annually. Insurance plans change, copay card benefits reset in January, and foundation funds open and close. What worked last year may not work this year.

Designate a Point Person

Financial navigation for specialty medications is complex. If your practice or institution has any of the following, leverage them:

• Social workers
• Patient navigators
• Financial counselors
• Specialty pharmacy liaisons

If not, consider designating a nurse or medical assistant to own the financial assistance workflow. Create a simple checklist: copay card enrolled → PA submitted → specialty pharmacy contacted → foundation applications checked. This prevents patients from falling through the cracks.

Quick Reference: Vijoice Financial Assistance Checklist

Use this at the point of prescribing:

1. ☐ Is the patient commercially insured? → Enroll in Novartis Co-Pay Program (up to $15,000/year)
2. ☐ Is the patient on Medicare? → Check PAN Foundation and other independent funds
3. ☐ Is the patient uninsured or underinsured? → Apply to NPAF (free medication)
4. ☐ Has prior authorization been submitted?
5. ☐ Has the specialty pharmacy been contacted?
6. ☐ Does the patient know about Medfinder for Providers for pharmacy availability?

Final Thoughts

The cost of Vijoice is a real barrier, but it's rarely an insurmountable one. Between Novartis's copay program, patient assistance foundation, and independent charity funds, most patients can access this medication at significantly reduced cost—or for free. The key is proactive enrollment and ongoing monitoring.

Your role as a provider isn't just to prescribe the right medication—it's to make sure your patient can actually take it. Building cost conversations and financial navigation into your standard workflow for specialty medications like Vijoice is one of the highest-impact things you can do for adherence and outcomes.

For more provider resources on managing PROS patients on Vijoice, see our guides on Vijoice shortage updates for providers and how to help patients find Vijoice in stock.